Edition:
United Kingdom

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

3.80USD
9:00pm BST
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$3.80
Open
$3.78
Day's High
$3.89
Day's Low
$3.70
Volume
412,539
Avg. Vol
493,067
52-wk High
$6.16
52-wk Low
$1.85

Latest Key Developments (Source: Significant Developments)

Catalyst Pharmaceuticals Says Entered Into Settlement Agreement With Northwestern University Resolving All Disputes
Friday, 24 May 2019 

May 24 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS- ON MAY 21, ENTERED INTO SETTLEMENT AGREEMENT WITH NORTHWESTERN UNIVERSITY THAT RESOLVED ALL PENDING DISPUTES BETWEEN PARTIES.CATALYST PHARMACEUTICALS INC - UNDER SETTLEMENT AGREEMENT, COMPANY IS ALSO ENTITLED TO RECEIVE CERTAIN CONTINGENT COMPENSATION.  Full Article

Bernie Sanders Says Will Ask FDA Commissioner To Act If Catalyst Pharma Does Not Address Concerns He Raised
Thursday, 21 Feb 2019 

Feb 21 (Reuters) - :BERNIE SANDERS PROVIDES STATEMENT ON CATALYST PHARMACEUTICALS' RESPONSE TO HIS FEB. 4 LETTER.BERNIE SANDERS SAYS "IF CATALYST IS UNWILLING TO ADDRESS THE CONCERNS I HAVE RAISED", WILL ASK FDA COMMISSIONER GOTTLIEB TO ACT IMMEDIATELY.BERNIE SANDERS, ON FIRDAPSE PRICING, SAYS FDA MUST ALLOW PHARMACIES, MANUFACTURERS WHO WERE PREVIOUSLY MAKING THIS DRUG TO BE PERMITTED TO RESUME PROVIDING IT.  Full Article

Catalyst Pharmaceuticals Responds To Feb. 4 Letter From Senator Bernie Sanders
Thursday, 21 Feb 2019 

Feb 21 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS RESPONDS TO LETTER FROM SENATOR BERNIE SANDERS.CATALYST PHARMACEUTICALS INC - HAS RESPONDED TO FEBRUARY 4, 2019 LETTER THAT COMPANY RECEIVED FROM SENATOR BERNIE SANDERS.CATALYST PHARMA - BELIEVE PRICING OF FIRDAPSEG IS IN LINE WITH PRICING OF OTHER PRODUCTS PROVIDING SIGNIFICANT CLINICAL BENEFITS IN TREATING ULTRA-ORPHAN DISEASE OF SIMILAR SEVERITY.CATALYST PHARMA - BELIEVE PRICING OF FIRDAPSEG IN LINE TO COMPENSATE COS FOR COSTS OF DEVELOPING, MANUFACTURING, MARKETING ORPHAN DRUG IN COMPLIANCE WITH REGULATORY REQUIREMENTS.CATALYST PHARMA - BELIEVE DRUG WILL BE WIDELY COVERED, REIMBURSED BY PRIVATE & PUBLIC PAYERS FOR INDICATED SMALL POPULATION OF ADULT LEN-IS PATIENTS.CATALYST PHARMA- FORECASTED REBATES, DISCOUNTS, PATIENT COMMERCIAL CO-PAY SUPPORT, AMONG OTHERS, WILL RESULT IN NET SALE PRICE BEING 15-20% LOWER THAN ANNUAL LIST PRICE FOR PRODUCT.CATALYST PHARMA- FORECASTED MEDICARE COVERAGE GAP SUBSIDIES, STATUTORY MEDICAID DISCOUNTS WILL ALSO RESULT IN NET SALE PRICE BEING 15-20% LOWER THAN ANNUAL LIST PRICE FOR PRODUCT.CATALYST PHARMA- FORECASTED OTHER GOVERNMENTAL DISCOUNTS WILL ALSO RESULT IN NET SALE PRICE BEING 15-20% LOWER THAN ANNUAL LIST PRICE FOR PRODUCT.  Full Article

Catalyst Pharmaceuticals Phase IIb Study Evaluating Firdapse Meets Main Goals
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES PUBLICATION OF CLINICAL DATA FROM THE INVESTIGATOR-SPONSORED PHASE IIB STUDY EVALUATING FIRDAPSE® FOR THE TREATMENT OF MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS.CATALYST PHARMACEUTICALS INC - CO-PRIMARY ENDPOINTS WERE STATISTICALLY MET IN STUDY.CATALYST PHARMACEUTICALS INC - SECONDARY ENDPOINTS STATISTICALLY MET IN STUDY.  Full Article

FDA Approves Firdapse For The Treatment Of Lambert-Eaton Myasthenic Syndrome
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Catalyst Pharmaceuticals Inc ::FDA APPROVES FIRDAPSE® (AMIFAMPRIDINE) FOR THE TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS).CATALYST PHARMACEUTICALS INC - FIRDAPSE IS EXPECTED TO BE COMMERCIALLY AVAILABLE EARLY IN Q1 OF 2019.  Full Article

Catalyst Pharmaceuticals GAAP Loss Per Share $0.08
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 GAAP LOSS PER SHARE $0.08.Q3 EARNINGS PER SHARE VIEW $-0.08 -- THOMSON REUTERS I/B/E/S.BELIEVES THAT ITS EXISTING CAPITAL RESOURCES WILL BE SUFFICIENT TO SUPPORT ITS PLANNED OPERATIONS THROUGH 2019.  Full Article

Catalyst Pharmaceuticals Announces Q4 Gaap Loss Per Share $0.06
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 GAAP LOSS PER SHARE $0.06.Q4 EARNINGS PER SHARE VIEW $-0.06 -- THOMSON REUTERS I/B/E/S.‍CATALYST HAD NO REVENUES IN YEAR 2017 OR 2016​.CATALYST PHARMACEUTICALS - ‍BASED ON CURRENT FINANCIAL POSITION, CASH FORECAST CO BELIEVES IT HAS SUFFICIENT FUNDS TO SUPPORT OPERATIONS THROUGH 2019​.  Full Article

Catalyst Pharmaceuticals Announces Plans To Resubmit New Drug Application For Firdapse
Monday, 12 Feb 2018 

Feb 12 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES PLANS TO RESUBMIT NEW DRUG APPLICATION FOR FIRDAPSE®.CATALYST PHARMACEUTICALS - CURRENTLY ANTICIPATES RESUBMITTING NDA FOR FIRDAPSE FOR LEMS TO FDA BY END OF Q1 2018.  Full Article

Great Point Partners Reports 5.14 Pct Passive Stake In Catalyst Pharma
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Catalyst Pharmaceuticals Inc ::GREAT POINT PARTNERS LLC REPORTS A 5.14 PERCENT PASSIVE STAKE IN CATALYST PHARMACEUTICALS INC AS OF NOV 28 - SEC FILING.  Full Article

Catalyst Pharma Announces Proposed Public Offering Of Common Stock
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 11.0 MILLION COMMON SHARES.CATALYST-PLANS TO USE PROCEEDS TO FUND CLINICAL STUDIES OF FIRDAPSE FOR TREATMENT OF MUSK-ANTIBODY POSITIVE MYASTHENIA GRAVIS,SPINAL MUSCULAR ATROPHY​.- PLANS TO USE NET PROCEEDS FROM OFFERING TO FUND PRE-COMMERCIALIZATION ACTIVITIES FOR FIRDAPSE​.  Full Article

UPDATE 2-Catalyst Pharma sues FDA over approval of cheaper rival drug

June 12 Catalyst Pharmaceuticals Inc, which has come under fire for the high price tag on its rare disease drug, on Wednesday sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival drug.